Holen Sie sich die Stockscreener-App
2.09
0.48%
0.010
Vorhandelsmarkt:
2.10
0.01
+0.48%
Schlusskurs vom Vortag:
$2.08
Offen:
$2.09
24-Stunden-Volumen:
1.89M
Relative Volume:
0.62
Marktkapitalisierung:
$92.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.50M
KGV:
-0.5225
EPS:
-4
Netto-Cashflow:
$-47.10M
1W Leistung:
+6.09%
1M Leistung:
+65.87%
6M Leistung:
+13.90%
1J Leistung:
+29.81%
1-Tages-Spanne:
$2.03
$2.13
1-Wochen-Bereich:
$1.93
$2.13
52-Wochen-Spanne:
$0.79
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Vergleichen Sie OTLK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
2.09 | 92.39M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of "Hold" by Analysts - MarketBeat
How Outlook Therapeutics Inc. (41ON) stock performs during market turbulenceTrade Risk Report & Free High Return Stock Watch Alerts - Newser
Is Outlook Therapeutics Inc. (41ON) stock worth buying before Fed actionMarket Trend Review & Free Real-Time Volume Trigger Notifications - Newser
Why Outlook Therapeutics Inc. (41ON) stock remains stableMarket Risk Report & Verified Short-Term Plans - Newser
Will Outlook Therapeutics Inc. (41ON) stock enhance shareholder value2025 Big Picture & Entry Point Confirmation Signals - Newser
How Outlook Therapeutics Inc. (41O) stock benefits from digital adoptionLong Setup & Weekly Market Pulse Alerts - Newser
How Outlook Therapeutics Inc. (41O) stock moves in volatile trading sessionsJuly 2025 Patterns & Fast Entry High Yield Tips - Newser
Will Outlook Therapeutics Inc. (41O) stock enhance shareholder valuePortfolio Return Report & Smart Money Movement Alerts - Newser
How Outlook Therapeutics Inc. stock benefits from tech adoptionEarnings Risk Summary & Real-Time Chart Breakout Alerts - Newser
What hedge fund moves indicate for Outlook Therapeutics Inc. (41O) stockJuly 2025 Rallies & Free Safe Entry Trade Signal Reports - Newser
How Outlook Therapeutics Inc. (41O) stock expands through international marketsOil Prices & Low Drawdown Investment Strategies - Newser
How Outlook Therapeutics Inc. (41O) stock trades under stagflationSwing Trade & Accurate Intraday Trading Signals - Newser
Will Outlook Therapeutics Inc. (41ON) stock maintain strong growthJuly 2025 Chart Watch & Free Technical Pattern Based Buy Signals - Newser
Can Outlook Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Value Summary & Daily Stock Trend Watchlist - Newser
Why institutional investors increase stakes in Outlook Therapeutics Inc. (41ON) stockWeekly Volume Report & Real-Time Market Sentiment Reports - Newser
Can Outlook Therapeutics Inc. (41O) stock stage a strong rebound this quarterEarnings Risk Summary & Weekly High Conviction Trade Ideas - Newser
Is Outlook Therapeutics Inc. (41O) stock a defensive play amid uncertaintyEarnings Overview Summary & Stock Portfolio Risk Management - Newser
Will Outlook Therapeutics Inc. (41O) stock beat value stocksMarket Trend Review & Low Risk Profit Maximizing Plans - Newser
Is Outlook Therapeutics Inc. (41ON) stock a top pick for value investors - Newser
How strong is Outlook Therapeutics Inc. (41ON) stock earnings growthPortfolio Value Summary & High Conviction Investment Ideas - Newser
Outlook Therapeutics (OTLK) Stock Analysis Report | Financials & Insights - Benzinga
Stock Report: What makes Outlook Therapeutics Inc stock attractive to growth fundsMarket Sentiment Report & Technical Entry and Exit Alerts - BỘ NỘI VỤ
Outlook Therapeutics, Inc. (OTLK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Risk Analysis: Can Outlook Therapeutics Inc. (41ON) stock resist broad market declinesQuarterly Growth Report & AI Forecasted Stock Moves - BỘ NỘI VỤ
Outlook Therapeutics Inc. (OTLK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How Outlook Therapeutics Inc. (41ON) stock trades under stagflationMarket Trend Review & Breakout Confirmation Alerts - BỘ NỘI VỤ
Can Outlook Therapeutics Inc. stock surprise with earnings upside2025 Biggest Moves & Daily Profit Maximizing Tips - BỘ NỘI VỤ
What drives Outlook Therapeutics Inc 41ON stock priceQuarterly Earnings Review & Access Risk Ratings for Every Stock - earlytimes.in
Outlook Therapeutics CEO Bob Jahr to Speak at Piper Sandler 37th Annual Healthcare Conference - Quiver Quantitative
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
What Macro Risks Could Undermine RCI Industries Technologies Limiteds ForecastMarket Rumors and News & Explosive Capital Growth Plans - earlytimes.in
Why Outlook Therapeutics Inc. stock is a must watch in 20252025 Fundamental Recap & Reliable Price Breakout Alerts - newser.com
Outlook Therapeutics’ FDA Review for ONS-5010 Resubmission - MSN
Is Outlook Therapeutics Inc. (41ON) stock expanding market penetrationJuly 2025 Summary & Free Long-Term Investment Growth Plans - newser.com
Is Outlook Therapeutics Inc. (41ON) stock cheap vs fundamentalsWeekly Trading Summary & Weekly High Potential Stock Alerts - newser.com
What analyst consensus implies for Outlook Therapeutics Inc. (41O) stockWeekly Trade Report & Weekly Breakout Stock Alerts - newser.com
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):